U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Plasma Cell Neoplasm

MedGen UID:
1753779
•Concept ID:
C5419571
•
Neoplastic Process

Definition

The reemergence of a plasma cell neoplasm after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Plasma Cell Neoplasm

Professional guidelines

PubMed

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol 2022 Aug;97(8):1086-1107. Epub 2022 May 23 doi: 10.1002/ajh.26590. PMID: 35560063Free PMC Article
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN
JAMA 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003. PMID: 35103762

Recent clinical studies

Etiology

Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F, Dogan A, Cook JR
Virchows Arch 2023 Jan;482(1):163-177. Epub 2022 Nov 21 doi: 10.1007/s00428-022-03431-3. PMID: 36414803Free PMC Article
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol 2022 Aug;97(8):1086-1107. Epub 2022 May 23 doi: 10.1002/ajh.26590. PMID: 35560063Free PMC Article
Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P
Blood Cancer J 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3. PMID: 35314675Free PMC Article
Roadmap to cure multiple myeloma.
Rodriguez-Otero P, Paiva B, San-Miguel JF
Cancer Treat Rev 2021 Nov;100:102284. Epub 2021 Aug 31 doi: 10.1016/j.ctrv.2021.102284. PMID: 34597912
Multiple myeloma: Every year a new standard?
Rajkumar SV
Hematol Oncol 2019 Jun;37 Suppl 1(Suppl 1):62-65. doi: 10.1002/hon.2586. PMID: 31187526Free PMC Article

Diagnosis

Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F, Dogan A, Cook JR
Virchows Arch 2023 Jan;482(1):163-177. Epub 2022 Nov 21 doi: 10.1007/s00428-022-03431-3. PMID: 36414803Free PMC Article
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol 2022 Aug;97(8):1086-1107. Epub 2022 May 23 doi: 10.1002/ajh.26590. PMID: 35560063Free PMC Article
Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P
Blood Cancer J 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3. PMID: 35314675Free PMC Article
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN
JAMA 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003. PMID: 35103762
Roadmap to cure multiple myeloma.
Rodriguez-Otero P, Paiva B, San-Miguel JF
Cancer Treat Rev 2021 Nov;100:102284. Epub 2021 Aug 31 doi: 10.1016/j.ctrv.2021.102284. PMID: 34597912

Therapy

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S
N Engl J Med 2023 Mar 16;388(11):1002-1014. Epub 2023 Feb 10 doi: 10.1056/NEJMoa2213614. PMID: 36762851
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol 2022 Aug;97(8):1086-1107. Epub 2022 May 23 doi: 10.1002/ajh.26590. PMID: 35560063Free PMC Article
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD Jr
Future Oncol 2022 Jan;18(3):277-289. Epub 2021 Dec 2 doi: 10.2217/fon-2021-1090. PMID: 34854741
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J
N Engl J Med 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850. PMID: 33626253

Prognosis

Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F, Dogan A, Cook JR
Virchows Arch 2023 Jan;482(1):163-177. Epub 2022 Nov 21 doi: 10.1007/s00428-022-03431-3. PMID: 36414803Free PMC Article
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P
Blood Cancer J 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3. PMID: 35314675Free PMC Article
Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
He H, Li Z, Lu J, Qiang W, Jiang S, Xu Y, Fu W, Zhai X, Zhou L, Qian M, Du J
Clin Transl Med 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757. PMID: 35297204Free PMC Article
Multiple myeloma: Every year a new standard?
Rajkumar SV
Hematol Oncol 2019 Jun;37 Suppl 1(Suppl 1):62-65. doi: 10.1002/hon.2586. PMID: 31187526Free PMC Article

Clinical prediction guides

A rational approach to functional high-risk myeloma.
Gay F, Bertuglia G, Mina R
Hematology Am Soc Hematol Educ Program 2023 Dec 8;2023(1):433-442. doi: 10.1182/hematology.2023000443. PMID: 38066896Free PMC Article
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
He H, Li Z, Lu J, Qiang W, Jiang S, Xu Y, Fu W, Zhai X, Zhou L, Qian M, Du J
Clin Transl Med 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757. PMID: 35297204Free PMC Article
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN
JAMA 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003. PMID: 35103762
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ
Leukemia 2020 Apr;34(4):985-1005. Epub 2020 Feb 13 doi: 10.1038/s41375-020-0734-z. PMID: 32055000Free PMC Article

Recent systematic reviews

Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A, Gaio M, Liguori V, Cagnotta C, Paolino D, Paolisso G, Castaldo G, Nicoletti GF, Rossi F, Capuano A, Rafaniello C
Pharmacol Res 2023 Apr;190:106742. Epub 2023 Mar 22 doi: 10.1016/j.phrs.2023.106742. PMID: 36963592
CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R
Eur J Haematol 2022 Dec;109(6):601-618. Epub 2022 Sep 18 doi: 10.1111/ejh.13851. PMID: 36018500
Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P
Blood Cancer J 2022 Mar 21;12(3):45. doi: 10.1038/s41408-022-00643-3. PMID: 35314675Free PMC Article
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS
J Clin Oncol 2021 Dec 10;39(35):3959-3977. Epub 2021 Jul 29 doi: 10.1200/JCO.21.01392. PMID: 34324367Free PMC Article
Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J
Int J Med Sci 2021;18(8):1786-1797. Epub 2021 Feb 18 doi: 10.7150/ijms.46811. PMID: 33746596Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...